SCHEMBL1675451

SCHEMBL1675451

O=C(Cn1c(C(=O)NCC2CCN(c3ccncc3)CC2)cc2ccccc21)Nc1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
F10 P00742 19/20 0.59
F2 P00734 3/20 0.56
KDM1A O60341 1/20 0.46
RCOR1 Q9UKL0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1675288 0.88 F10 (0.72) F10F2
SCHEMBL8355000 0.88 F10 (0.69) F10F2
SCHEMBL15911648 0.86 F10 (0.47) F10F2
SCHEMBL13900111 0.84 F10 (0.58) F10
SCHEMBL8357795 0.83 F10 (0.64) F10
SCHEMBL1675021 0.81 F10 (0.67) F10F2
SCHEMBL8358925 0.81 F10 (0.59) F10F2
SCHEMBL8358639 0.79 F10 (0.58) F10
SCHEMBL15911529 0.78 F10 (0.55) F10F2
SCHEMBL1675028 0.76 F10 (0.59) F10F2KDM1ARCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4664592-B2 2011-04-06 JP claimed
EP-1451185-B1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2014-08-06 EP disclosed
US-20090069565-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-03-12 US disclosed
US-20090069565-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069565-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS F12, F5, F2 F10 10/4885F2 3/4885KDM1A 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.